Course / Fertility Treatment
For patients with Polycystic Ovary Syndrome (PCOS) who experience anovulation (absence of ovulation), the primary goal is to restore regular ovulation. Oral medications such as clomiphene citrate (CC) and letrozole are commonly used as first-line treatments for this purpose. Both medications function by stimulating the brain to produce gonadotropins, hormones that play a crucial role in triggering ovulation.
Clomiphene citrate, a selective estrogen receptor modulator (SERM), works by blocking estrogen receptors in the brain, preventing it from sensing circulating estrogen levels, thereby encouraging gonadotropin production. Letrozole, on the other hand, is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing overall estrogen levels. Despite their differing mechanisms, both drugs aim to restore proper gonadotropin function, thereby enabling ovulation. Both are orally administered and more cost-effective than injectable gonadotropins.
Evidence suggests that letrozole may be more effective than clomiphene citrate in inducing ovulation and live birth in PCOS patients, leading many clinicians to recommend letrozole as the first-line treatment, with clomiphene citrate reserved for patients who do not respond.
A pivotal study published in the New England Journal of Medicine (2014) evaluated live birth rates in PCOS patients undergoing up to five cycles of treatment with either letrozole or clomiphene citrate. The study was large (750 participants), randomized, and conducted across multiple centers. Limitations included the primarily Caucasian patient population, a relatively high dropout rate, and a follow-up limited to three years for offspring outcomes.
Success Rates:
Letrozole demonstrated superior ovulation and live birth rates overall. Notably, the benefit of letrozole was most pronounced in patients with a BMI over 30, while patients with BMI under 30 had more comparable outcomes between the two drugs.
Risk of Multiple Pregnancies:
Letrozole generally leads to fewer multiple pregnancies than clomiphene citrate, which is clinically significant because multiple gestation pregnancies carry increased maternal and fetal risks. PCOS patients are more likely to develop multiple follicles simultaneously, heightening the risk of twins or triplets. Studies have shown that letrozole promotes mono-follicular growth, similar to gonadotropins, whereas clomiphene citrate is less likely to do so. These findings support letrozole as the preferred initial therapy in PCOS.
Offspring Safety:
A major concern with letrozole historically was its potential effect on the offspring. The 2014 NEJM study reported 5–6% incidence of serious adverse events (congenital anomalies, fetal or neonatal death) for both letrozole and clomiphene citrate, similar to the baseline population rate of 5.8%. Thus, neither drug appears to increase the risk of significant adverse outcomes in offspring.
Other Adverse Effects:
Letrozole: fatigue, dizziness
Clomiphene citrate: hot flashes
Endometrial Receptivity:
Successful implantation requires a receptive endometrium. Letrozole is generally considered superior to clomiphene citrate in maintaining endometrial receptivity. While clomiphene citrate may reduce uterine blood flow during the luteal phase, letrozole maintains a more natural uterine environment, crucial for embryo implantation.
Metformin, an insulin sensitizer, reduces hepatic glucose production, enhances peripheral glucose uptake, and lowers circulating insulin levels. In PCOS, lower insulin reduces ovarian androgen production, which can improve ovulation. Metformin may be combined with clomiphene citrate or letrozole in patients who remain anovulatory, though gastrointestinal side effects can occur.
Effectiveness:
With clomiphene citrate: improves ovulation and pregnancy rates; live birth rates similar to clomiphene alone.
With letrozole: evidence shows limited additional benefit.
Considerations:
Metformin should be discontinued upon confirmation of pregnancy, as prolonged exposure may impact offspring weight.
DEX, a steroid, targets adrenal androgen excess in patients with elevated DHEA-S. Studies combining DEX with clomiphene citrate show improved ovulation and pregnancy rates. However, side effects such as weight gain, mood changes, and potential bone loss limit its routine use.
LOD is a surgical procedure that uses electrocautery or laser to puncture ovaries, potentially reducing androgen and inhibin levels and stimulating follicular development. Success rates for inducing ovulation range from 30–90%. LOD also reduces the risk of multiple pregnancies and OHSS, though surgical risks such as adhesions, ovarian damage, bleeding, and anesthesia-related complications exist. It is generally considered second-line therapy after failure of oral medications.
Objective: To describe the minor surgical procedure used to collect the eggs from the ovaries.
Content:
The egg retrieval is a minimally invasive procedure performed under intravenous sedation, so the patient experiences no discomfort.
The Procedure: Guided by a transvaginal ultrasound, a fertility physician inserts a thin needle through the vaginal wall to access each ovary. The fluid from each follicle is gently aspirated.
Immediate Lab Work: The follicular fluid is immediately handed to the embryologist in the adjacent lab, who examines it under a microscope to identify the eggs.
Recovery & Aftercare: The procedure typically takes 20-30 minutes. Patients recover for about an hour before being discharged. Mild cramping or bloating is normal for a day or two following the procedure.
The total number of eggs retrieved is reported on the same day. It is important to note that not every follicle will necessarily contain a mature, viable egg.
Gonadotropins are injectable hormones that directly stimulate follicle development. They are used when oral medications fail or in combination with IUI or IVF.
Considerations:
Higher cost and administration burden.
Requires close monitoring to prevent multiple gestations and OHSS.
Initial dosing for PCOS patients is typically 37.5–75 IU/day, lower than standard doses, with incremental adjustments.
Adjunctive Therapies:
Metformin or letrozole can be added to reduce OHSS risk.
GnRH-antagonist protocols further reduce OHSS while maintaining success rates.
Intrauterine Insemination (IUI):
Less invasive and costly, but lower success rates, especially in women >40 years or with male factor infertility.
Monitoring is crucial to avoid multifollicular development and multiple pregnancies.
IVF (In Vitro Fertilization):
Most effective, especially for older patients or those with blocked fallopian tubes, severe endometriosis, male factor infertility, or recurrent pregnancy loss.
PCOS patients often achieve comparable or higher success rates than other groups.
Requires careful gonadotropin dosing and monitoring to minimize OHSS.
Fresh vs. Frozen embryo transfer: Frozen transfers can reduce OHSS and improve uterine receptivity, particularly in PCOS patients with obesity.
Adjunctive Considerations:
Metformin can improve pregnancy rates and reduce OHSS risk during IVF cycles.
Antagonist protocols and GnRH agonist triggers can further mitigate OHSS risk.
For patients with PCOS, intrauterine insemination (IUI) can be considered as a fertility treatment when ovulation is induced with medications. However, PCOS patients face unique challenges due to the higher likelihood of developing multiple follicles, which increases the risk of multiple gestation pregnancies—posing risks to both the patient and the offspring.
Because PCOS patients are prone to multiple follicle development, it is crucial to undergo IUI at a clinic equipped to monitor follicular growth via ultrasound. Monitoring ensures that the number of developing follicles is tracked, allowing the physician to:
Adjust medication doses to favor monofollicular growth (growth of a single dominant follicle).
Decide whether to cancel the cycle if too many follicles are developing, reducing the risk of twins or triplets.
IUI is usually paired with ovulation-inducing medications:
Oral medications: Letrozole or clomiphene citrate.
Injectable gonadotropins: Reserved for patients who do not respond to oral therapy.
Data Insights:
Oral medications plus IUI in PCOS patients provide modest success rates but carry a lower risk of multiple pregnancies.
IUI with gonadotropins can improve success rates but significantly increases the risk of twins or triplets, requiring close monitoring and careful dose adjustments.
Letrozole is generally preferred as the first-choice oral medication in PCOS patients starting IUI.
Evidence from a large study of 750 women showed higher live birth rates and fewer multiple gestations with letrozole compared to clomiphene citrate.
The benefit of letrozole is particularly notable in patients with BMI over 30 kg/m², where it nearly doubled live birth rates compared to clomiphene citrate.
Adding IUI to an oral ovulation regimen is most useful when:
There is a mild male factor infertility.
Ovulation has resumed but pregnancy has not occurred.
For PCOS patients just beginning oral ovulation therapy, starting with letrozole plus IUI offers a balanced approach, combining reasonable success rates with lower risk of multiples.
Close monitoring is essential to manage the risk of multiple pregnancies.
Letrozole is generally superior to clomiphene citrate in live birth outcomes and reducing multiples.
IUI is most effective when paired with medications and applied in selected patient scenarios, rather than as a blanket first-line treatment.
By carefully managing medications, monitoring follicular development, and tailoring the approach to individual patient factors, IUI can be a safe and moderately effective fertility option for women with PCOS.
For women with PCOS, in vitro fertilization (IVF) is often the most effective fertility treatment, particularly when other interventions like oral medications or IUI have failed. Although IVF is more invasive, time-consuming, and costly, it offers higher success rates and allows for precise control over egg retrieval, fertilization, and embryo transfer.
Women with PCOS generally experience comparable or even higher IVF success rates than patients with other infertility causes.
Data from the U.S. SART database indicates that after three IVF cycles, PCOS patients maintain strong live birth outcomes, often outperforming other diagnostic groups.
Age remains a crucial factor, with younger PCOS patients having the highest likelihood of success.
IVF requires the production of multiple eggs, achieved through injectable gonadotropins. PCOS patients are at heightened risk of developing ovarian hyperstimulation syndrome (OHSS) due to their high ovarian reserve.
Key considerations for drug protocols:
Goal: Stimulate enough eggs for multiple embryo options while minimizing OHSS risk.
Monitoring: Close ultrasound monitoring is critical to track follicle growth and adjust medication doses.
Protocol Choice: Using a GnRH antagonist protocol (instead of agonist) helps suppress premature ovulation and significantly lowers the risk of OHSS.
Triggering Final Maturation: Selecting GnRH agonist instead of hCG to trigger oocyte maturation reduces OHSS risk further.
Metformin may be added to IVF protocols for PCOS patients to reduce OHSS risk.
Meta-analyses suggest that metformin can improve pregnancy rates in PCOS patients, though live birth rates may not differ significantly.
Side effects are generally mild to moderate (e.g., gastrointestinal discomfort), and metformin should be discontinued once pregnancy is confirmed.
After fertilization, embryos can be transferred either immediately (fresh transfer) or after freezing (frozen transfer).
For PCOS patients:
Frozen transfers are often preferred because they allow the uterine environment to normalize and reduce OHSS risk.
Strong ovarian responses in PCOS can disrupt endometrial receptivity during fresh transfers, particularly in patients with obesity.
Studies indicate higher live birth rates and lower OHSS incidence with frozen transfers, although there may be a slightly increased risk of preeclampsia.
IVF is generally recommended when:
Oral medications and IUI have failed after multiple attempts.
There are severe male factor infertility issues.
The patient has recurrent pregnancy loss or genetic conditions that require embryo testing.
Tubal factor infertility exists (e.g., blocked fallopian tubes).
IVF provides high success rates for PCOS patients, especially when properly monitored and using antagonist protocols.
OHSS risk is a primary concern; strategies include protocol selection, metformin co-administration, and potentially freezing embryos.
Individualized treatment planning is critical, considering age, BMI, ovarian response, and previous fertility attempts.
By combining careful drug protocol selection, close monitoring, and appropriate embryo transfer strategies, IVF can be a safe and highly effective fertility solution for women with PCOS.
Our job is to listen, to connect the dots between your needs, and to determine how we can best help you have your baby. If you’re asking how much does it cost for a surrogate, we’ll walk you through every step of the process to ensure there are no surprises.
To make an appointment with one of our counselors or physicians, please call (212) 661-7673 or email info@surrogacy4all.com. We look forward to hearing from you.
Surrogacy4All is a unique international surrogacy service targeted at providing state of the art IVF and surrogacy services to Intended Parents irrespective of age, sex or color, at the lowest possible cost in the world.
Secret Guide to Minimizing Surrogacy Costs
All Rights Reserved to Surrogacy4all